“We expect the pace of repurchase to continue at this level given our strong balance sheet.”

In context

“for our shareholders. Our company is rapidly moving towards a future with a more diversified portfolio of growth drivers. As we continue to assess our business, we are likely to take actions that will seek to maximize the potential of these opportunities by investing with discipline while transforming our business to drive continuous productivity across the company. We intend to communicate more about these efforts later this year. We remain committed to our dividend with the goal of increasing it over time. Business development remains an important priority. We continue to actively evaluate opportunities to execute additional science-driven value-creating transactions. We increased our share repurchases in the quarter to approximately $1.2 billion similar to the full-year amount in 2024. We expect the pace of repurchase to continue at this level given our strong balance sheet. Our top priority, however, remains to invest fully behind our growth drivers and pipeline, as well as business development. To conclude, we are confident in the outlook for our business driven by our strong portfolio and exceptional pipeline. With investment in innovation, and our ongoing focus on execution we are well-positioned to deliver value to patients, customers, and shareholders now and well into the future. With that, I'd now like to turn the call over to Dean. Dr. Dean Li: Thank you, Caroline. Good morning. Progress continued in the first quarter with a steady cadence of positive clinical and regulatory milestones. Today, I will provide updates from programs in cardiometabolic disease, HIV, vaccines, and we'll close with oncology. Starting with cardiometabolic disease, since its”